ABAXIS SG&A Expense: 13.21M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ABAX SG&A Expense Rankings
| Overall | 58th percentile | 1820 of 4398 |
| Sector | 39th percentile | 308 of 508 in Healthcare |
| Industry | 11th percentile | 16 of 18 in Diagnostic Substances |
ABAX SG&A Expense Range, Past 5 Years
| Minimum | 0.22M | Dec 1991 |
| Maximum | 6.92M | Sep 2006 |
| Average |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these ABAX related companies
ABAX News
Canaccord Genuity Reiterates a 'Hold' on Abaxis Inc. (ABAX); Misses on Top and Bottom Lines; Lowering Estimates & PT
Jan 27, 10:19AM Street Insider
Jan 27, 10:19AM Street Insider
Listen to $ABAX Q3 2012 earnings call - live at 04:15 PM, ondemand after - http://stks.co/272d
about 17 days ago by earningscast
about 17 days ago by earningscast
Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2012
Jan 26, 4:00PM PR Newswire
Jan 26, 4:00PM PR Newswire
Abaxis to Report Third Quarter Fiscal Year 2012 Financial Results Thursday, January 26, 2012
Jan 26, 7:45AM PR Newswire
Jan 26, 7:45AM PR Newswire
Abaxis to Report Third Quarter Fiscal Year 2012 Financial Results Thursday, January 26, 2012
Jan 17, 7:00AM PR Newswire
Jan 17, 7:00AM PR Newswire
Canaccord Genuity Starts Abaxis Inc. (ABAX) at Hold; Vet and Medical Markets Show Signs of Stabilizing
Jan 06, 8:55AM Street Insider
Jan 06, 8:55AM Street Insider
Abaxis (ABAX) Veterinary Division Announces Development of Quantitative Lyme Test
Dec 27, 8:03AM Street Insider
Dec 27, 8:03AM Street Insider
Abaxis Veterinary Reference Laboratories Now Offering Quantitative Lyme Test
Dec 27, 8:01AM Benzinga
Dec 27, 8:01AM Benzinga
Abaxis, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
Nov 22, 8:00AM PR Newswire
Nov 22, 8:00AM PR Newswire
$ABAX http://chart.ly/hkccquu Nice move yest. on strong volume closed near HoD. Setting up to challenge recent highs.
about 340 days ago by TheEquitiesRoom
about 340 days ago by TheEquitiesRoom
$ABAX not like $ebix, neg. volume, higher PE with less growth- be careful
about 347 days ago by akminer
about 347 days ago by akminer
5 Set-ups for Thursday. http://bit.ly/hOcej1 $ABAX $CSX $NSC $MTL $VIT
about 347 days ago by PatternProfits
about 347 days ago by PatternProfits
$ABAX http://chart.ly/e97y5fx Stalking this symm. triangle b/o over $27. High short interest also makes it a squeeze candidate.
about 347 days ago by PatternProfits
about 347 days ago by PatternProfits
$ABAX more shares sold by $SEVERSON CLINTON. See holders at http://tinyurl.com/2bs2nva
about 430 days ago by whalewisdom
about 430 days ago by whalewisdom
$ABAX upgraded from Mkt Perform to Mkt Outperform http://bit.ly/bbuT7e #nasdaq
about 572 days ago by NASDAQ
about 572 days ago by NASDAQ
http://chart.ly/6by5dx $ABAX - RT @Briefingcom Avondale ups to Mkt Outperform // Monthly techs look like bottom rail could be tested.
about 572 days ago by Xiphos_Trading
about 572 days ago by Xiphos_Trading
Trade: CALENDAR on $ABAX: -3 JAN10 25 / +3 MAY10 25 CALLS 2.33 http://bit.ly/7XeDS3
about 776 days ago by dbjret
about 776 days ago by dbjret
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ABAX | 27.49 | -0.41 | -1.47% | 595.98M |
| DRYS | 3.00 | -0.06 | -1.96% | 1.23B |
| PSS | 18.45 | -0.03 | -0.16% | 1.12B |
| TLEO | 45.66 | 0.01 | 0.03% | 1.89B |
| LOPE | 17.71 | 0.24 | 1.37% | 784.38M |
| GOOD | 18.38 | -0.08 | -0.43% | 201.08M |
| URBN | 27.00 | -0.41 | -1.48% | 4.16B |
| CRM | 128.44 | 2.83 | 2.25% | 17.40B |
| IMAX | 21.22 | -0.38 | -1.76% | 1.37B |
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
